ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010
Clinical pharmacology in the adolescent oncology patient.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Differential efficacy of empirical antibiotic therapy for febrile neutropenia in adolescent/young adult (AYA) and child patients.International journal of hematology · 2018Trial
- Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004.Haematologica · 2016Trial
- Ontogeny and sorafenib metabolism.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Trial
- Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.Haematologica · 2012Trial
- Article
- Article
- Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci.The pharmacogenomics journal · 2024Article
- Association of platinum-based chemotherapy with live birth and infertility in female survivors of adolescent and young adult cancer.Fertility and sterility · 2024Article
- 'Only to reconcile with it'. The coping experience amongst middle-aged and older cancer survivors: A qualitative study.Health expectations : an international journal of public participation in health care and health policy · 2024Article
- The Capacity of Drug-Metabolising Enzymes in Modulating the Therapeutic Efficacy of Drugs to Treat Rhabdomyosarcoma.Cancers · 2024Review
- Acute toxicity of chemotherapy in central nervous system germ cell tumour patients according to age.Frontiers in oncology · 2024Article
- Nutritional status, body composition and diet quality in children with cancer.Frontiers in oncology · 2024Review
- Shedding a Light on the Challenges of Adolescents and Young Adults with Rhabdomyosarcoma.Cancers · 2022Review
- Review
- Systems-Level Change to Alleviate Barriers to Cancer Clinical Trial Access for Adolescents and Young Adults in Australia.Journal of adolescent and young adult oncology · 2022Article
- Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event-free survival in intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group.Pediatric blood & cancer · 2021Article
- Gynecological cancer among adolescents and young adults (AYA).Annals of translational medicine · 2020Review
- Outcomes of allogeneic hematopoietic cell transplant for acute myeloid leukemia in adolescent patients.Bone marrow transplantation · 2020Article
- Current situation of cancer among adolescents and young adults in Japan.International journal of clinical oncology · 2018Article
- Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE.Annals of oncology : official journal of the European Society for Medical Oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Numerous studies have documented that adolescents and young adults (AYAs) experience a significant cancer burden as well as significant cancer mortality compared with other age groups. The reasons for the disparate outcomes of AYAs and other age groups are not completely understood and are likely to be multifactorial, including a range of sociodemographic issues unique to these individuals as well as differences between adolescents, younger pediatric patients, and adults in the pharmacology of anticancer agents. Because adolescence is a period of transition from childhood to early adulthood, numerous physical, physiologic, cognitive, and behavioral changes occur during this time. In this review, we provide an overview of the unique developmental physiology of the adolescent and explain how these factors and the behavioral characteristics of adolescents may affect the pharmacology of anticancer agents in this patient population. Finally, we describe examples of studies that have assessed the relation between drug disposition and age, focusing on the AYA age group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.